In the latest trading session, Cathie Wood's ARK ETFs exhibited a blend of strategic buys and sells, with Roku Inc (NASDAQ:ROKU) and Twist Bioscience Corp (NASDAQ:TWST) leading the purchases. On Friday, April 12, 2024, ARK's flagship funds engaged in several significant transactions, reflecting Wood's ongoing confidence in the biotech and tech sectors.
ARK's largest buy for the day was in Roku Inc (NASDAQ:ROKU), where the funds scooped up 66,301 shares across ARKK and ARKW, amounting to a substantial investment of $4,107,347. This move signals ARK's bullish stance on the streaming platform, which has been a recurring theme in the fund's recent activity.
Twist Bioscience Corp (NASDAQ:TWST), a synthetic biology company, also saw a major influx of capital from ARK with the purchase of 132,782 shares, valued at $4,339,315. The consistent accumulation of TWST shares underscores ARK's optimism about the company's growth prospects in the burgeoning field of genetic research.
In the biotech space, ARK continued to increase its positions, buying 56850 shares of Arcturus Therapeutics (NASDAQ:ARCT) Holdings Inc (NASDAQ:ARCT) for $1,849,899, and adding 371,597 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) at a total value of $3,314,645. Both companies are working on innovative treatments that could potentially disrupt the healthcare market.
Telemedicine also remained in focus, with ARK purchasing 192,277 shares of Teladoc Health Inc (NYSE:NYSE:TDOC) across multiple funds, totaling an investment of $2,807,244. This acquisition aligns with ARK's thematic investment in digital health technologies, which Wood has frequently championed.
On the sell side, ARK offloaded shares in several companies, including a sale of 202,466 shares of Nu Holdings Ltd (NYSE:NU) for $2,338,482 and 2743 shares of Nvidia Corp (NASDAQ:NVDA) at a value of $2,485,596. These divestitures may reflect ARK's portfolio rebalancing or a strategic shift in response to market conditions.
Other notable trades included the sale of 8115 shares of Exact Sciences Corp (NASDAQ:EXAS) for $591,989 and 35727 shares of UiPath Inc (NYSE:NYSE:PATH) valued at $761,342, indicating a possible reallocation of resources within the healthcare and tech sectors.
ARK's daily trades reveal a strategic emphasis on genomic innovation and technology platforms, with a pattern of reinforcing positions in companies poised for long-term growth. Investors following ARK's movements may find these trends indicative of the fund's broader investment thesis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.